Vinva Investment Management Ltd trimmed its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 9.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 84,553 shares of the biopharmaceutical company's stock after selling 8,691 shares during the quarter. Vinva Investment Management Ltd's holdings in Gilead Sciences were worth $7,780,000 at the end of the most recent reporting period.
Other large investors have also recently added to or reduced their stakes in the company. State Street Corp grew its position in shares of Gilead Sciences by 1.4% during the 3rd quarter. State Street Corp now owns 60,171,691 shares of the biopharmaceutical company's stock worth $5,044,795,000 after purchasing an additional 841,776 shares in the last quarter. Wellington Management Group LLP boosted its stake in shares of Gilead Sciences by 50.9% in the third quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company's stock valued at $2,900,921,000 after buying an additional 11,665,593 shares during the period. FMR LLC grew its position in Gilead Sciences by 79.4% during the third quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company's stock worth $2,780,329,000 after buying an additional 14,680,161 shares in the last quarter. Geode Capital Management LLC increased its stake in Gilead Sciences by 2.1% during the 3rd quarter. Geode Capital Management LLC now owns 27,540,870 shares of the biopharmaceutical company's stock worth $2,302,119,000 after acquiring an additional 574,421 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its holdings in Gilead Sciences by 3.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 8,002,779 shares of the biopharmaceutical company's stock valued at $739,217,000 after acquiring an additional 249,804 shares in the last quarter. Institutional investors own 83.67% of the company's stock.
Gilead Sciences Stock Performance
Shares of GILD stock traded up $1.21 during trading on Friday, hitting $107.08. The company's stock had a trading volume of 26,496,292 shares, compared to its average volume of 6,793,320. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. The company has a market cap of $133.35 billion, a PE ratio of 289.41, a P/E/G ratio of 0.71 and a beta of 0.21. The business has a fifty day moving average of $103.68 and a 200-day moving average of $93.85. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $119.96.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. As a group, research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.
Gilead Sciences Increases Dividend
The business also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be paid a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.95%. This is a boost from Gilead Sciences's previous quarterly dividend of $0.77. The ex-dividend date is Friday, March 14th. Gilead Sciences's payout ratio is presently 854.05%.
Analyst Upgrades and Downgrades
GILD has been the topic of a number of recent analyst reports. Royal Bank of Canada raised their price target on Gilead Sciences from $84.00 to $90.00 and gave the stock a "sector perform" rating in a research report on Wednesday, February 12th. DZ Bank raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 target price on the stock in a report on Thursday, February 13th. Bank of America upped their price target on shares of Gilead Sciences from $116.00 to $126.00 and gave the stock a "buy" rating in a report on Wednesday, March 5th. BMO Capital Markets lifted their price objective on shares of Gilead Sciences from $110.00 to $115.00 and gave the company an "outperform" rating in a research note on Wednesday, February 12th. Finally, JPMorgan Chase & Co. upped their target price on Gilead Sciences from $105.00 to $115.00 and gave the stock an "overweight" rating in a research note on Wednesday, January 29th. Eleven research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have assigned a strong buy rating to the company. According to data from MarketBeat, Gilead Sciences presently has a consensus rating of "Moderate Buy" and an average target price of $104.52.
Check Out Our Latest Stock Report on GILD
Insider Activity
In related news, CFO Andrew D. Dickinson sold 17,929 shares of Gilead Sciences stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $118.17, for a total value of $2,118,669.93. Following the completion of the sale, the chief financial officer now owns 169,061 shares of the company's stock, valued at approximately $19,977,938.37. This trade represents a 9.59 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders sold 302,785 shares of company stock valued at $30,503,250 in the last three months. Company insiders own 0.29% of the company's stock.
Gilead Sciences Company Profile
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Featured Articles
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
